 | • レポートコード：QYR9ST01455 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界の黒色腫用薬市場について調査・分析し、以下の構成でお届け致します。黒色腫用薬の種類別には、化学療法、免疫療法、標的療法に、用途別には、病院、診療所、その他に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別黒色腫用薬売上データ ・地域別黒色腫用薬市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別黒色腫用薬市場規模：化学療法、免疫療法、標的療法 ・用途別黒色腫用薬市場規模：病院、診療所、その他 ・主要メーカーの企業情報：Amgen、Bristol-Myers Squibb、Roche、Genentech、Janssen Biotech、Novartis、Pfizer、Sanofi、Takeda Pharma、Teva Pharma ・黒色腫用薬の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the skin and is most common because most pigment cells are found in the skin. Mucosal melanoma is melanoma of mucous membrane of the body, including the mouth, the nasal passages, the throat, the vagina or the anus. The rare ocular melanoma or uveal melanoma occurs in the eye.The global Drugs for Melanoma market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drugs for Melanoma market based on company, product type, end user and key regions.
This report studies the global market size of Drugs for Melanoma in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Drugs for Melanoma in these regions.
This research report categorizes the global Drugs for Melanoma market by top players/brands, region, type and end user. This report also studies the global Drugs for Melanoma market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
Bristol-Myers Squibb
Roche
Genentech
Janssen Biotech
Novartis
Pfizer
Sanofi
Takeda Pharma
Teva Pharma
Market size by Product
Chemotherapy
Immunotherapy
Targeted Therapy
Market size by End User
Hospitals
Clinics
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Drugs for Melanoma market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Drugs for Melanoma market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Drugs for Melanoma companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Drugs for Melanoma submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Drugs for Melanoma are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Drugs for Melanoma market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 Drugs for Melanoma Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Drugs for Melanoma Market Size Growth Rate by Product
1.4.2 Chemotherapy
1.4.3 Immunotherapy
1.4.4 Targeted Therapy
1.5 Market by End User
1.5.1 Global Drugs for Melanoma Market Size Growth Rate by End User
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Drugs for Melanoma Market Size
2.1.1 Global Drugs for Melanoma Revenue 2014-2025
2.1.2 Global Drugs for Melanoma Sales 2014-2025
2.2 Drugs for Melanoma Growth Rate by Regions
2.2.1 Global Drugs for Melanoma Sales by Regions
2.2.2 Global Drugs for Melanoma Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Drugs for Melanoma Sales by Manufacturers
3.1.1 Drugs for Melanoma Sales by Manufacturers
3.1.2 Drugs for Melanoma Sales Market Share by Manufacturers
3.1.3 Global Drugs for Melanoma Market Concentration Ratio (CR5 and HHI)
3.2 Drugs for Melanoma Revenue by Manufacturers
3.2.1 Drugs for Melanoma Revenue by Manufacturers (2014-2019)
3.2.2 Drugs for Melanoma Revenue Share by Manufacturers (2014-2019)
3.3 Drugs for Melanoma Price by Manufacturers
3.4 Drugs for Melanoma Manufacturing Base Distribution, Product Types
3.4.1 Drugs for Melanoma Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Drugs for Melanoma Product Type
3.4.3 Date of International Manufacturers Enter into Drugs for Melanoma Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Drugs for Melanoma Sales by Product
4.2 Global Drugs for Melanoma Revenue by Product
4.3 Drugs for Melanoma Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Drugs for Melanoma Breakdown Data by End User
6 North America
6.1 North America Drugs for Melanoma by Countries
6.1.1 North America Drugs for Melanoma Sales by Countries
6.1.2 North America Drugs for Melanoma Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Drugs for Melanoma by Product
6.3 North America Drugs for Melanoma by End User
7 Europe
7.1 Europe Drugs for Melanoma by Countries
7.1.1 Europe Drugs for Melanoma Sales by Countries
7.1.2 Europe Drugs for Melanoma Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Drugs for Melanoma by Product
7.3 Europe Drugs for Melanoma by End User
8 Asia Pacific
8.1 Asia Pacific Drugs for Melanoma by Countries
8.1.1 Asia Pacific Drugs for Melanoma Sales by Countries
8.1.2 Asia Pacific Drugs for Melanoma Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Drugs for Melanoma by Product
8.3 Asia Pacific Drugs for Melanoma by End User
9 Central & South America
9.1 Central & South America Drugs for Melanoma by Countries
9.1.1 Central & South America Drugs for Melanoma Sales by Countries
9.1.2 Central & South America Drugs for Melanoma Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Drugs for Melanoma by Product
9.3 Central & South America Drugs for Melanoma by End User
10 Middle East and Africa
10.1 Middle East and Africa Drugs for Melanoma by Countries
10.1.1 Middle East and Africa Drugs for Melanoma Sales by Countries
10.1.2 Middle East and Africa Drugs for Melanoma Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Drugs for Melanoma by Product
10.3 Middle East and Africa Drugs for Melanoma by End User
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Company Business Overview
11.1.3 Amgen Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Amgen Drugs for Melanoma Products Offered
11.1.5 Amgen Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Company Business Overview
11.2.3 Bristol-Myers Squibb Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Bristol-Myers Squibb Drugs for Melanoma Products Offered
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Company Business Overview
11.3.3 Roche Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Roche Drugs for Melanoma Products Offered
11.3.5 Roche Recent Development
11.4 Genentech
11.4.1 Genentech Company Details
11.4.2 Company Business Overview
11.4.3 Genentech Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Genentech Drugs for Melanoma Products Offered
11.4.5 Genentech Recent Development
11.5 Janssen Biotech
11.5.1 Janssen Biotech Company Details
11.5.2 Company Business Overview
11.5.3 Janssen Biotech Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Janssen Biotech Drugs for Melanoma Products Offered
11.5.5 Janssen Biotech Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Company Business Overview
11.6.3 Novartis Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Novartis Drugs for Melanoma Products Offered
11.6.5 Novartis Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Company Business Overview
11.7.3 Pfizer Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Pfizer Drugs for Melanoma Products Offered
11.7.5 Pfizer Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Company Business Overview
11.8.3 Sanofi Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Sanofi Drugs for Melanoma Products Offered
11.8.5 Sanofi Recent Development
11.9 Takeda Pharma
11.9.1 Takeda Pharma Company Details
11.9.2 Company Business Overview
11.9.3 Takeda Pharma Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Takeda Pharma Drugs for Melanoma Products Offered
11.9.5 Takeda Pharma Recent Development
11.10 Teva Pharma
11.10.1 Teva Pharma Company Details
11.10.2 Company Business Overview
11.10.3 Teva Pharma Drugs for Melanoma Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Teva Pharma Drugs for Melanoma Products Offered
11.10.5 Teva Pharma Recent Development
12 Future Forecast
12.1 Drugs for Melanoma Market Forecast by Regions
12.1.1 Global Drugs for Melanoma Sales Forecast by Regions 2019-2025
12.1.2 Global Drugs for Melanoma Revenue Forecast by Regions 2019-2025
12.2 Drugs for Melanoma Market Forecast by Product
12.2.1 Global Drugs for Melanoma Sales Forecast by Product 2019-2025
12.2.2 Global Drugs for Melanoma Revenue Forecast by Product 2019-2025
12.3 Drugs for Melanoma Market Forecast by End User
12.4 North America Drugs for Melanoma Forecast
12.5 Europe Drugs for Melanoma Forecast
12.6 Asia Pacific Drugs for Melanoma Forecast
12.7 Central & South America Drugs for Melanoma Forecast
12.8 Middle East and Africa Drugs for Melanoma Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Drugs for Melanoma Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure Drugs for Melanoma Product Picture
Table Drugs for Melanoma Market Segments
Table Key Manufacturers Drugs for Melanoma Covered
Table Global Drugs for Melanoma Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$)
Figure Global Drugs for Melanoma Sales Market Share by Product 2014-2025
Figure Chemotherapy Product Picture
Table Major Manufacturers of Chemotherapy
Figure Immunotherapy Product Picture
Table Major Manufacturers of Immunotherapy
Figure Targeted Therapy Product Picture
Table Major Manufacturers of Targeted Therapy
Table Global Drugs for Melanoma Market Size Growth Rate by End User 2019-2025 (K Units)
Figure Hospitals
Figure Clinics
Figure Others
Figure Drugs for Melanoma Report Years Considered
Figure Global Drugs for Melanoma Market Size 2014-2025 (Million US$)
Figure Global Drugs for Melanoma Sales 2014-2025 (K Units)
Table Global Drugs for Melanoma Market Size by Regions 2014-2019 (K Units) & (Million US$)
Table Global Drugs for Melanoma Sales by Regions 2014-2019 (K Units)
Table Global Drugs for Melanoma Sales Market Share by Regions 2014-2019
Figure Global Drugs for Melanoma Sales Market Share by Regions 2014-2019
Figure 2018 Global Drugs for Melanoma Sales Market Share by Regions
Table Global Drugs for Melanoma Revenue by Regions 2014-2019 (Million US$)
Table Global Drugs for Melanoma Revenue Market Share by Regions 2014-2019
Figure Global Drugs for Melanoma Revenue Market Share by Regions 2014-2019
Figure 2018 Global Drugs for Melanoma Revenue Market Share by Regions
Table Global Drugs for Melanoma Sales by Manufacturers (2014-2019) (K Units)
Table Global Drugs for Melanoma Sales Share by Manufacturers (2014-2019)
Figure Global Drugs for Melanoma Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Drugs for Melanoma Revenue by Manufacturers (2014-2019) (Million USD)
Table Drugs for Melanoma Revenue Share by Manufacturers (2014-2019)
Figure Drugs for Melanoma Value Share by Manufacturers in 2018
Table Key Manufacturers Drugs for Melanoma Price (2014-2019) (USD/Unit)
Table Drugs for Melanoma Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Drugs for Melanoma Product Type
Table Date of International Manufacturers Enter into Drugs for Melanoma Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Drugs for Melanoma Sales by Product (2014-2019) (K Units)
Table Global Drugs for Melanoma Sales Share by Product (2014-2019)
Figure Global Drugs for Melanoma Sales Market Share by Product (2014-2019)
Figure Global Drugs for Melanoma Sales Market Share by Product in 2018
Table Global Drugs for Melanoma Revenue by Product (2014-2019) (Million US$)
Table Global Drugs for Melanoma Revenue Share by Product (2014-2019)
Figure Global Drugs for Melanoma Revenue Market Share by Product (2014-2019)
Figure Global Drugs for Melanoma Revenue Market Share by Product in 2018
Table Drugs for Melanoma Price by Product 2014-2019 (USD/Unit)
Table Global Drugs for Melanoma Sales by End User (2014-2019) (K Units)
Table Global Drugs for Melanoma Sales Share by End User (2014-2019)
Figure Global Sales Drugs for Melanoma Market Share by End User (2014-2019)
Figure Global Sales Drugs for Melanoma Market Share by End User in 2018
Figure North America Drugs for Melanoma Sales Growth Rate 2014-2019 (K Units)
Figure North America Drugs for Melanoma Revenue Growth Rate 2014-2019 (Million US$)
Table North America Drugs for Melanoma Sales by Countries (2014-2019) (K Units)
Table North America Drugs for Melanoma Sales Market Share by Countries (2014-2019)
Figure 2018 North America Drugs for Melanoma Sales Market Share by Countries
Table North America Drugs for Melanoma Revenue by Countries (2014-2019) (Million US$)
Table North America Drugs for Melanoma Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Drugs for Melanoma Revenue Market Share by Countries
Figure United States Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure United States Drugs for Melanoma Revenue Growth Rate (2014-2019) (K Units)
Figure Canada Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Canada Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Mexico Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Table North America Drugs for Melanoma Sales by Product (2014-2019) (K Units)
Table North America Drugs for Melanoma Sales Market Share by Product (2014-2019)
Figure 2018 North America Drugs for Melanoma Market Share by Product
Table North America Drugs for Melanoma Sales by End User (2014-2019) (K Units)
Table North America Drugs for Melanoma Sales Market Share by End User (2014-2019)
Figure 2018 North America Drugs for Melanoma Market Share by End User
Figure Europe Drugs for Melanoma Sales Growth Rate 2014-2019 (K Units)
Figure Europe Drugs for Melanoma Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Drugs for Melanoma Sales by Countries (2014-2019) (K Units)
Table Europe Drugs for Melanoma Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Drugs for Melanoma Sales Market Share by Countries
Table Europe Drugs for Melanoma Revenue by Countries (2014-2019) (Million US$)
Table Europe Drugs for Melanoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Drugs for Melanoma Revenue Market Share by Countries
Figure Germany Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Germany Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure France Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure France Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure UK Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Italy Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Russia Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Drugs for Melanoma Sales by Product (2014-2019) (K Units)
Table Europe Drugs for Melanoma Sales Market Share by Product (2014-2019)
Figure 2018 Europe Drugs for Melanoma Market Share by Product
Table Europe Drugs for Melanoma Sales by End User (2014-2019) (K Units)
Table Europe Drugs for Melanoma Sales Market Share by End User (2014-2019)
Figure 2018 Europe Drugs for Melanoma Market Share by End User
Figure Asia Pacific Drugs for Melanoma Sales Growth Rate 2014-2019 (K Units)
Figure Asia Pacific Drugs for Melanoma Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Drugs for Melanoma Sales by Countries (2014-2019) (K Units)
Table Asia Pacific Drugs for Melanoma Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Drugs for Melanoma Sales Market Share by Countries
Table Asia Pacific Drugs for Melanoma Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Drugs for Melanoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Drugs for Melanoma Revenue Market Share by Countries
Figure China Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure China Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Japan Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Korea Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure India Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure India Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Australia Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Indonesia Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Malaysia Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Philippines Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Thailand Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Vietnam Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Singapore Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Drugs for Melanoma Sales by Product (2014-2019) (K Units)
Table Asia Pacific Drugs for Melanoma Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Drugs for Melanoma Market Share by Product
Table Asia Pacific Drugs for Melanoma Sales by End User (2014-2019) (K Units)
Table Asia Pacific Drugs for Melanoma Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Drugs for Melanoma Market Share by End User
Figure Central & South America Drugs for Melanoma Sales Growth Rate 2014-2019 (K Units)
Figure Central & South America Drugs for Melanoma Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Drugs for Melanoma Sales by Countries (2014-2019) (K Units)
Table Central & South America Drugs for Melanoma Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Drugs for Melanoma Sales Market Share by Countries
Table Central & South America Drugs for Melanoma Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Drugs for Melanoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Drugs for Melanoma Revenue Market Share by Countries
Figure Brazil Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Brazil Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Argentina Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Drugs for Melanoma Sales by Product (2014-2019) (K Units)
Table Central & South America Drugs for Melanoma Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Drugs for Melanoma Market Share by Product
Table Central & South America Drugs for Melanoma Sales by End User (2014-2019) (K Units)
Table Central & South America Drugs for Melanoma Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Drugs for Melanoma Market Share by End User
Figure Middle East and Africa Drugs for Melanoma Sales Growth Rate 2014-2019 (K Units)
Figure Middle East and Africa Drugs for Melanoma Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Drugs for Melanoma Sales by Countries (2014-2019) (K Units)
Table Middle East and Africa Drugs for Melanoma Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Drugs for Melanoma Sales Market Share by Countries
Table Middle East and Africa Drugs for Melanoma Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Drugs for Melanoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Drugs for Melanoma Revenue Market Share by Countries
Figure GCC Countries Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure GCC Countries Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Turkey Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure Egypt Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Drugs for Melanoma Sales Growth Rate (2014-2019) (K Units)
Figure South Africa Drugs for Melanoma Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Drugs for Melanoma Sales by Product (2014-2019) (K Units)
Table Middle East and Africa Drugs for Melanoma Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Drugs for Melanoma Market Share by Product
Table Middle East and Africa Drugs for Melanoma Sales by End User (2014-2019) (K Units)
Table Middle East and Africa Drugs for Melanoma Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Drugs for Melanoma Market Share by End User
Table Amgen Company Details
Table Amgen Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Amgen Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Roche Company Details
Table Roche Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Roche Recent Development
Table Genentech Company Details
Table Genentech Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Genentech Recent Development
Table Janssen Biotech Company Details
Table Janssen Biotech Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Janssen Biotech Recent Development
Table Novartis Company Details
Table Novartis Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Novartis Recent Development
Table Pfizer Company Details
Table Pfizer Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Pfizer Recent Development
Table Sanofi Company Details
Table Sanofi Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Sanofi Recent Development
Table Takeda Pharma Company Details
Table Takeda Pharma Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Takeda Pharma Recent Development
Table Teva Pharma Company Details
Table Teva Pharma Drugs for Melanoma Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Teva Pharma Recent Development
Table Global Drugs for Melanoma Sales Forecast by Regions 2019-2025 (K Units)
Table Global Drugs for Melanoma Sales Market Share Forecast by Regions 2019-2025
Table Global Drugs for Melanoma Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Drugs for Melanoma Revenue Market Share Forecast by Regions 2019-2025
Table Global Drugs for Melanoma Sales Forecast by Product 2019-2025 (K Units)
Table Global Drugs for Melanoma Sales Market Share Forecast by Product 2019-2025
Table Global Drugs for Melanoma Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Drugs for Melanoma Revenue Market Share Forecast by Product 2019-2025
Table Global Drugs for Melanoma Sales Forecast by End User 2019-2025 (K Units)
Table Global Drugs for Melanoma Sales Market Share Forecast by End User 2019-2025
Figure North America Drugs for Melanoma Sales Growth Rate Forecast (2019-2025) (K Units)
Figure North America Drugs for Melanoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Drugs for Melanoma Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Europe Drugs for Melanoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Drugs for Melanoma Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Asia Pacific Drugs for Melanoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Drugs for Melanoma Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Central & South America Drugs for Melanoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Drugs for Melanoma Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Middle East and Africa Drugs for Melanoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Drugs for Melanoma Value Chain
Table Drugs for Melanoma Customers List
Table Drugs for Melanoma Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
非黒色腫皮膚癌の世界市場：市場規模・現状・予測 Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts.Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikel…- タイサブリ薬の世界市場：インサイト・予測 Tysabri (natalizumab) is a monoclonal antibody used in to treat relapsing forms of multiple sclerosis. Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this con…
- 免疫療法薬の世界市場：市場規模・現状・予測 Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system.North America is expected to account for largest share in the i…
- 泌尿生殖器薬の世界市場：インサイト・予測 A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases.The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of pi…
- 細菌性膣炎薬の世界市場：インサイト・予測 Bacterial vaginosis is an imbalance of "good" and "bad" bacteria in the vagina, with there being more bad bacteria. Causes of an imbalance of bacteria can be caused by multiple sex partners and douching. Symptoms include odor, discharge, burning, and itching. Treatments for bacterial vaginosis inclu…